Persistent IFN-γ signaling also allows the tumor to acquire signal transducer and activator of transcription 1 (STAT1)-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T-cell inhibitory receptors, which can be seen as a mechanism of adaptive resistance to checkpoint inhibitor therapy. The gene discussed is IFNG; the disease is neoplasm.